ALLEGRO-DVT/V-NOVA
8.12.2022 18:33:41 CET | Business Wire | Press release
Allegro DVT, the leading provider of video codec compliance test suites and semiconductor video IPs, and V-Nova, a leading provider of video compression solutions today announce a partnership to accelerate the availability of LCEVC enabled solutions for Video SOCs and ASIC vendors looking at faster time-to-market in the deployment of LCEVC.
The two companies will collaborate to address the growing demand for LCEVC with a target to make available both compliance test streams and proven video IPs. This new product roadmap will enable video SOC and video ASIC vendors in a multitude of different markets to integrate and verify the compliance of their LCVEC implementation with the standard, allowing for a safer tape-out and faster time-to-market.
Nouar Hamze, CEO, Allegro DVT said, “We were impressed with the performance of LCEVC both in terms of video quality and compression ratio. We also see it as an opportunity to tackle the increasing complexity of video codecs while delivering best-in-class power consumption. Allegro DVT is committed to supporting the LCEVC ecosystem and welcome the collaboration with V-Nova. Over the next months, we will be announcing a full range of new products to accelerate the design and testing of video SoCs targeting the LCEVC market.”
“We are excited to be collaborating with Allegro DVT to support the roll out of LCEVC in the market,” said Guido Meardi, CEO and co-founder at V-Nova. “They are the market leaders in the provision of compliance test streams to SOC vendors. These, together with proven silicon IP, will speed up the availability of LCEVC-enabled silicon in the market. We look forward to the partnership and further support Allegro’s LCEVC roadmap.”
LCEVC – the new video standard from MPEG – is at the vanguard of improving image quality, reducing latency, and boosting bandwidth. LCEVC is the first enhancement standard from MPEG, delivering better quality at up to 40% lower bandwidth, faster transcoding times, reduced costs for storage and content delivery. MPEG-5 LCEVC is an innovative standard that enhances any ‘base’ codec, including AVC/H.264, HEVC/H.265, VVC/H.266 and AV1 with no requirement to replace them.
About Allegro DVT
Allegro DVT, headquartered in Grenoble/France, is a world leading provider of digital video technology solutions including compliance streams and video codec semiconductor IPs focused on the H.264/AVC, H.265/HEVC, AVS2, AVS3, VP9, AV1 and VVC standards.
About V-Nova
V-Nova is committed to unlocking higher picture quality at scale. Its technologies, based on the innovative use of AI and parallel processing improve data, video, imaging, point-cloud compression and have been granted international standard status by MPEG, ISO and SMPTE. Our relentless investment in R&D has built a portfolio of over 600 international patents which we monetize through software licensing, IP royalties and product sales. For more about V-Nova, please visit: www.v-nova.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005048/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom